| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 119 | 2023 | 11538 | 5.080 |
Why?
|
| Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase | 10 | 2023 | 23 | 4.690 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 11 | 2023 | 159 | 3.790 |
Why?
|
| Golgi Apparatus | 6 | 2023 | 147 | 3.160 |
Why?
|
| Epithelial-Mesenchymal Transition | 15 | 2023 | 973 | 2.810 |
Why?
|
| Bronchi | 23 | 2017 | 326 | 2.500 |
Why?
|
| Tretinoin | 25 | 2007 | 623 | 2.410 |
Why?
|
| MAP Kinase Kinase 4 | 12 | 2017 | 142 | 2.320 |
Why?
|
| Collagen | 10 | 2023 | 752 | 2.250 |
Why?
|
| Receptors, Retinoic Acid | 21 | 2006 | 365 | 2.100 |
Why?
|
| Adenocarcinoma | 35 | 2022 | 7789 | 1.960 |
Why?
|
| Cancer-Associated Fibroblasts | 4 | 2021 | 107 | 1.960 |
Why?
|
| Genes, ras | 14 | 2012 | 667 | 1.840 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 50 | 2022 | 5319 | 1.780 |
Why?
|
| Extracellular Matrix | 7 | 2020 | 554 | 1.770 |
Why?
|
| Cell Line, Tumor | 50 | 2023 | 14551 | 1.470 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2021 | 327 | 1.370 |
Why?
|
| MicroRNAs | 12 | 2023 | 2947 | 1.370 |
Why?
|
| Epithelial Cells | 14 | 2021 | 1818 | 1.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 29 | 2023 | 8873 | 1.160 |
Why?
|
| Respiratory Mucosa | 8 | 2010 | 206 | 1.150 |
Why?
|
| Neoplasm Proteins | 6 | 2020 | 3230 | 1.120 |
Why?
|
| Cell Movement | 12 | 2023 | 2466 | 1.120 |
Why?
|
| Collagen Type I | 3 | 2022 | 204 | 1.100 |
Why?
|
| Fibroblasts | 10 | 2022 | 1682 | 1.080 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2020 | 315 | 1.060 |
Why?
|
| Mice | 64 | 2022 | 34495 | 1.050 |
Why?
|
| Neoplasm Metastasis | 18 | 2021 | 5112 | 1.040 |
Why?
|
| Tumor Suppressor Protein p53 | 11 | 2021 | 3552 | 1.020 |
Why?
|
| Animals | 82 | 2022 | 59536 | 1.010 |
Why?
|
| Smoking | 19 | 2014 | 2440 | 0.970 |
Why?
|
| Mitogen-Activated Protein Kinases | 8 | 2016 | 639 | 0.880 |
Why?
|
| ErbB Receptors | 14 | 2014 | 2295 | 0.860 |
Why?
|
| Precancerous Conditions | 11 | 2008 | 1058 | 0.850 |
Why?
|
| RNA, Neoplasm | 6 | 2021 | 771 | 0.840 |
Why?
|
| Signal Transduction | 30 | 2023 | 11965 | 0.810 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 2021 | 43 | 0.800 |
Why?
|
| Endosomes | 1 | 2021 | 109 | 0.780 |
Why?
|
| Tumor Cells, Cultured | 22 | 2015 | 5395 | 0.780 |
Why?
|
| Glucosyltransferases | 1 | 2021 | 54 | 0.780 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 9 | 2006 | 301 | 0.770 |
Why?
|
| Retinoids | 9 | 2006 | 164 | 0.760 |
Why?
|
| Vesicular Transport Proteins | 1 | 2021 | 135 | 0.710 |
Why?
|
| Membrane Proteins | 11 | 2021 | 2819 | 0.700 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2020 | 129 | 0.680 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 5 | 2003 | 371 | 0.680 |
Why?
|
| Anticarcinogenic Agents | 8 | 2007 | 362 | 0.670 |
Why?
|
| Humans | 150 | 2023 | 261506 | 0.670 |
Why?
|
| Calcium-Binding Proteins | 2 | 2013 | 545 | 0.660 |
Why?
|
| Gene Amplification | 2 | 2021 | 731 | 0.660 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 4 | 2008 | 74 | 0.650 |
Why?
|
| Phosphatidylinositol 3-Kinases | 9 | 2016 | 1678 | 0.650 |
Why?
|
| Disease Models, Animal | 15 | 2022 | 7222 | 0.650 |
Why?
|
| Mimiviridae | 1 | 2018 | 3 | 0.650 |
Why?
|
| Neoplasms | 11 | 2023 | 15193 | 0.630 |
Why?
|
| Transcription Factors | 12 | 2022 | 5270 | 0.620 |
Why?
|
| Thy-1 Antigens | 1 | 2017 | 51 | 0.610 |
Why?
|
| Ketoglutaric Acids | 1 | 2017 | 38 | 0.600 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2022 | 803 | 0.590 |
Why?
|
| Protein Multimerization | 1 | 2018 | 240 | 0.580 |
Why?
|
| Homeodomain Proteins | 4 | 2014 | 1143 | 0.580 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2017 | 73 | 0.580 |
Why?
|
| Receptors, Notch | 2 | 2011 | 383 | 0.580 |
Why?
|
| Disease Progression | 8 | 2021 | 6682 | 0.580 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2017 | 87 | 0.580 |
Why?
|
| Cross-Linking Reagents | 1 | 2017 | 153 | 0.580 |
Why?
|
| Antineoplastic Agents | 25 | 2018 | 14289 | 0.580 |
Why?
|
| Osteogenesis Imperfecta | 1 | 2018 | 140 | 0.570 |
Why?
|
| Cell Transformation, Neoplastic | 10 | 2008 | 2359 | 0.560 |
Why?
|
| Pulmonary Alveoli | 3 | 2011 | 208 | 0.560 |
Why?
|
| Gene Expression Profiling | 13 | 2021 | 5159 | 0.550 |
Why?
|
| Proteomics | 2 | 2023 | 1380 | 0.540 |
Why?
|
| Apoptosis | 21 | 2019 | 7591 | 0.530 |
Why?
|
| Neovascularization, Pathologic | 3 | 2020 | 1547 | 0.530 |
Why?
|
| Kruppel-Like Transcription Factors | 2 | 2014 | 270 | 0.530 |
Why?
|
| Lung | 15 | 2022 | 3151 | 0.530 |
Why?
|
| Cells, Cultured | 16 | 2015 | 5637 | 0.520 |
Why?
|
| Receptors, Progesterone | 2 | 2021 | 1392 | 0.520 |
Why?
|
| Viral Proteins | 1 | 2018 | 435 | 0.520 |
Why?
|
| Iron | 1 | 2018 | 376 | 0.500 |
Why?
|
| Teratocarcinoma | 5 | 1994 | 24 | 0.490 |
Why?
|
| Mutation | 18 | 2018 | 15179 | 0.480 |
Why?
|
| Transforming Growth Factor beta | 6 | 2021 | 1130 | 0.470 |
Why?
|
| Cyclin D1 | 5 | 2013 | 576 | 0.460 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2008 | 986 | 0.460 |
Why?
|
| Mice, 129 Strain | 5 | 2015 | 170 | 0.450 |
Why?
|
| Protein Kinases | 3 | 2007 | 874 | 0.440 |
Why?
|
| Secretory Vesicles | 2 | 2023 | 39 | 0.430 |
Why?
|
| Indoles | 3 | 2018 | 1009 | 0.430 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2015 | 2488 | 0.420 |
Why?
|
| Cell Communication | 2 | 2021 | 509 | 0.420 |
Why?
|
| Actin Cytoskeleton | 1 | 2012 | 82 | 0.420 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 7 | 2020 | 1331 | 0.420 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2009 | 650 | 0.400 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 6 | 2 | 2000 | 7 | 0.390 |
Why?
|
| Receptors, Interleukin-8B | 2 | 2012 | 56 | 0.390 |
Why?
|
| Cell Proliferation | 16 | 2022 | 7226 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2016 | 2054 | 0.380 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2020 | 5178 | 0.380 |
Why?
|
| Enzyme Activation | 6 | 2021 | 1764 | 0.370 |
Why?
|
| PPAR gamma | 1 | 2011 | 229 | 0.370 |
Why?
|
| Ligands | 7 | 2011 | 995 | 0.370 |
Why?
|
| Polyploidy | 3 | 2019 | 73 | 0.360 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 125 | 0.360 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 3 | 1999 | 206 | 0.350 |
Why?
|
| Extracellular Space | 1 | 2009 | 132 | 0.350 |
Why?
|
| Mice, Transgenic | 9 | 2021 | 4143 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-jun | 3 | 2006 | 166 | 0.340 |
Why?
|
| Cell Culture Techniques | 4 | 2013 | 598 | 0.340 |
Why?
|
| Ki-67 Antigen | 3 | 2010 | 666 | 0.340 |
Why?
|
| Lysine | 4 | 2023 | 422 | 0.340 |
Why?
|
| Tumor Suppressor Proteins | 8 | 2012 | 1823 | 0.330 |
Why?
|
| Ubiquitination | 2 | 2020 | 575 | 0.330 |
Why?
|
| Bronchoscopy | 6 | 2003 | 474 | 0.330 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2010 | 419 | 0.320 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 2004 | 215 | 0.320 |
Why?
|
| Blotting, Western | 10 | 2013 | 3536 | 0.320 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 101 | 0.320 |
Why?
|
| Phosphorylation | 10 | 2012 | 4804 | 0.310 |
Why?
|
| Bronchial Neoplasms | 3 | 2003 | 79 | 0.310 |
Why?
|
| Coculture Techniques | 4 | 2015 | 626 | 0.310 |
Why?
|
| Cell Cycle Proteins | 4 | 2004 | 2045 | 0.300 |
Why?
|
| Oncogene Protein v-akt | 1 | 2007 | 101 | 0.300 |
Why?
|
| Sulfones | 1 | 2008 | 143 | 0.300 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 3022 | 0.300 |
Why?
|
| Promoter Regions, Genetic | 8 | 2015 | 3101 | 0.290 |
Why?
|
| Transcription, Genetic | 7 | 2007 | 3154 | 0.290 |
Why?
|
| Genes, Reporter | 6 | 2012 | 798 | 0.290 |
Why?
|
| Isoenzymes | 3 | 2004 | 614 | 0.290 |
Why?
|
| NF-kappa B | 4 | 2008 | 1549 | 0.290 |
Why?
|
| Fenretinide | 4 | 2003 | 96 | 0.290 |
Why?
|
| Metaplasia | 6 | 2003 | 383 | 0.280 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2019 | 4757 | 0.280 |
Why?
|
| Indazoles | 2 | 2018 | 297 | 0.280 |
Why?
|
| Mutation, Missense | 2 | 2009 | 1152 | 0.280 |
Why?
|
| Cell Polarity | 2 | 2021 | 208 | 0.280 |
Why?
|
| Epidermal Growth Factor | 1 | 2008 | 423 | 0.280 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2009 | 589 | 0.280 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2021 | 5437 | 0.270 |
Why?
|
| Microradiography | 1 | 2005 | 5 | 0.270 |
Why?
|
| Tumor Microenvironment | 5 | 2021 | 2864 | 0.270 |
Why?
|
| Fibrosis | 2 | 2020 | 793 | 0.270 |
Why?
|
| Carcinoma, Small Cell | 7 | 2003 | 408 | 0.270 |
Why?
|
| Luciferases | 3 | 2017 | 445 | 0.270 |
Why?
|
| Protein Domains | 2 | 2017 | 314 | 0.260 |
Why?
|
| Cell Adhesion | 2 | 2022 | 1008 | 0.260 |
Why?
|
| MAP Kinase Signaling System | 1 | 2009 | 848 | 0.260 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2013 | 3639 | 0.260 |
Why?
|
| Enzyme Stability | 2 | 2018 | 105 | 0.260 |
Why?
|
| Pyrazoles | 3 | 2019 | 1471 | 0.260 |
Why?
|
| Culture Media, Conditioned | 3 | 2017 | 260 | 0.250 |
Why?
|
| Protein Binding | 4 | 2018 | 3438 | 0.250 |
Why?
|
| Transcriptional Activation | 4 | 2006 | 1070 | 0.250 |
Why?
|
| Rotenone | 1 | 2004 | 35 | 0.240 |
Why?
|
| Genes, p53 | 6 | 2014 | 1090 | 0.240 |
Why?
|
| Carrier Proteins | 4 | 2021 | 2022 | 0.240 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 854 | 0.240 |
Why?
|
| Male | 59 | 2022 | 123000 | 0.240 |
Why?
|
| src-Family Kinases | 1 | 2007 | 478 | 0.240 |
Why?
|
| Anaphase | 2 | 2020 | 44 | 0.230 |
Why?
|
| Lasers | 2 | 1999 | 198 | 0.230 |
Why?
|
| Cricetulus | 2 | 2017 | 205 | 0.230 |
Why?
|
| Epithelium | 7 | 2003 | 720 | 0.230 |
Why?
|
| Chromatography, Liquid | 3 | 2017 | 342 | 0.230 |
Why?
|
| Benzoates | 2 | 2002 | 136 | 0.230 |
Why?
|
| Hydroxylysine | 1 | 2023 | 2 | 0.230 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2020 | 1489 | 0.230 |
Why?
|
| Biomarkers, Tumor | 12 | 2021 | 10331 | 0.230 |
Why?
|
| CHO Cells | 2 | 2017 | 311 | 0.230 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2018 | 997 | 0.230 |
Why?
|
| Blotting, Northern | 8 | 2002 | 682 | 0.230 |
Why?
|
| Neoplasm Transplantation | 3 | 2022 | 1519 | 0.230 |
Why?
|
| Chemokines | 4 | 2008 | 314 | 0.230 |
Why?
|
| Secretory Pathway | 1 | 2023 | 16 | 0.220 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2022 | 216 | 0.220 |
Why?
|
| Genetic Therapy | 6 | 2003 | 1616 | 0.220 |
Why?
|
| Cytokines | 6 | 2020 | 2809 | 0.220 |
Why?
|
| Adenoviridae | 7 | 2003 | 1459 | 0.220 |
Why?
|
| Jagged-2 Protein | 3 | 2015 | 12 | 0.220 |
Why?
|
| Trimethylsilyl Compounds | 1 | 2002 | 2 | 0.220 |
Why?
|
| Up-Regulation | 3 | 2021 | 2450 | 0.220 |
Why?
|
| Transplantation, Heterologous | 3 | 2022 | 1082 | 0.220 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2017 | 368 | 0.210 |
Why?
|
| Stem Cells | 2 | 2011 | 1213 | 0.210 |
Why?
|
| RNA, Messenger | 13 | 2013 | 6150 | 0.210 |
Why?
|
| Adaptor Protein Complex sigma Subunits | 1 | 2021 | 5 | 0.210 |
Why?
|
| Focal Adhesions | 1 | 2021 | 45 | 0.200 |
Why?
|
| 1-Phosphatidylinositol 4-Kinase | 1 | 2021 | 17 | 0.200 |
Why?
|
| Gonanes | 2 | 2014 | 45 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 6207 | 0.200 |
Why?
|
| Protein Kinase C | 2 | 1993 | 396 | 0.200 |
Why?
|
| Alpha-Globulins | 1 | 2021 | 14 | 0.200 |
Why?
|
| Discoidin Domain Receptor 2 | 1 | 2021 | 10 | 0.200 |
Why?
|
| Transfection | 8 | 2020 | 2944 | 0.200 |
Why?
|
| Mice, Knockout | 9 | 2020 | 5710 | 0.200 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2015 | 194 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 1998 | 123 | 0.200 |
Why?
|
| Enzyme Inhibitors | 3 | 2018 | 1879 | 0.200 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2001 | 81 | 0.200 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2005 | 519 | 0.190 |
Why?
|
| Amino Acid Sequence | 5 | 2018 | 4233 | 0.190 |
Why?
|
| Endocytosis | 1 | 2021 | 225 | 0.190 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2000 | 153 | 0.190 |
Why?
|
| Sulfonamides | 1 | 2010 | 1823 | 0.190 |
Why?
|
| Sirolimus | 1 | 2005 | 814 | 0.190 |
Why?
|
| DNA, Antisense | 1 | 2000 | 42 | 0.190 |
Why?
|
| Cell Lineage | 3 | 2020 | 668 | 0.190 |
Why?
|
| Gene Deletion | 3 | 2016 | 1442 | 0.190 |
Why?
|
| DNA Primers | 4 | 2011 | 1399 | 0.190 |
Why?
|
| Immunohistochemistry | 10 | 2016 | 7548 | 0.190 |
Why?
|
| Cytoskeleton | 1 | 2021 | 267 | 0.180 |
Why?
|
| DNA-Binding Proteins | 7 | 2006 | 4821 | 0.180 |
Why?
|
| Gene Expression Regulation | 6 | 2017 | 4053 | 0.180 |
Why?
|
| Down-Regulation | 4 | 2012 | 2074 | 0.180 |
Why?
|
| Biological Transport | 1 | 2021 | 597 | 0.180 |
Why?
|
| Cell Survival | 4 | 2008 | 3045 | 0.180 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2007 | 1283 | 0.180 |
Why?
|
| Fluorescence | 2 | 1999 | 195 | 0.180 |
Why?
|
| Embryo, Mammalian | 2 | 2017 | 741 | 0.180 |
Why?
|
| STAT3 Transcription Factor | 2 | 2017 | 1121 | 0.170 |
Why?
|
| Cyclin E | 2 | 2013 | 267 | 0.170 |
Why?
|
| Retinoic Acid Receptor alpha | 3 | 2006 | 95 | 0.170 |
Why?
|
| Base Sequence | 6 | 2011 | 4917 | 0.170 |
Why?
|
| X-Ray Microtomography | 1 | 2020 | 141 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2020 | 249 | 0.170 |
Why?
|
| Transcriptome | 2 | 2021 | 1859 | 0.170 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2004 | 311 | 0.170 |
Why?
|
| Catalytic Domain | 3 | 2018 | 303 | 0.170 |
Why?
|
| Protein Transport | 1 | 2021 | 734 | 0.170 |
Why?
|
| Cell Division | 8 | 2004 | 2489 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2017 | 1439 | 0.170 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 309 | 0.170 |
Why?
|
| Actins | 1 | 2021 | 608 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2019 | 1756 | 0.160 |
Why?
|
| Immediate-Early Proteins | 1 | 1999 | 107 | 0.160 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 1998 | 43 | 0.160 |
Why?
|
| Female | 55 | 2021 | 141928 | 0.160 |
Why?
|
| Cisplatin | 9 | 2014 | 2432 | 0.160 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1999 | 182 | 0.160 |
Why?
|
| Smoking Cessation | 4 | 2008 | 712 | 0.160 |
Why?
|
| alpha-Tocopherol | 3 | 2007 | 78 | 0.160 |
Why?
|
| Aged | 43 | 2021 | 70117 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2021 | 15862 | 0.160 |
Why?
|
| Oncogenes | 3 | 2012 | 673 | 0.160 |
Why?
|
| Retinoblastoma Protein | 1 | 1999 | 335 | 0.160 |
Why?
|
| Fatty Acids | 1 | 2020 | 448 | 0.160 |
Why?
|
| Scattering, Small Angle | 1 | 2018 | 62 | 0.150 |
Why?
|
| Oncostatin M | 1 | 2017 | 23 | 0.150 |
Why?
|
| NF-kappa B p52 Subunit | 1 | 2017 | 26 | 0.150 |
Why?
|
| X-Ray Diffraction | 1 | 2018 | 168 | 0.150 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1999 | 214 | 0.150 |
Why?
|
| Organophosphates | 2 | 2015 | 41 | 0.150 |
Why?
|
| Succinic Acid | 1 | 2017 | 23 | 0.150 |
Why?
|
| Receptor, ErbB-3 | 2 | 2009 | 122 | 0.150 |
Why?
|
| Chemokines, CXC | 2 | 2008 | 117 | 0.150 |
Why?
|
| Retinoid X Receptors | 5 | 2002 | 85 | 0.150 |
Why?
|
| Middle Aged | 43 | 2021 | 86204 | 0.150 |
Why?
|
| In Vitro Techniques | 1 | 2020 | 1618 | 0.150 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 169 | 0.150 |
Why?
|
| Mice, Nude | 3 | 2020 | 4307 | 0.150 |
Why?
|
| Janus Kinase 1 | 1 | 2017 | 121 | 0.140 |
Why?
|
| Glycosylation | 1 | 2017 | 213 | 0.140 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 470 | 0.140 |
Why?
|
| Claudins | 1 | 2016 | 47 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1999 | 534 | 0.140 |
Why?
|
| RNA, Long Noncoding | 1 | 2022 | 598 | 0.140 |
Why?
|
| Stromal Cells | 1 | 2020 | 825 | 0.140 |
Why?
|
| Carbon | 1 | 2017 | 149 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2013 | 2508 | 0.140 |
Why?
|
| Ipilimumab | 1 | 2021 | 710 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 4 | 2012 | 3981 | 0.140 |
Why?
|
| Crystallography, X-Ray | 1 | 2018 | 627 | 0.140 |
Why?
|
| Tissue Array Analysis | 2 | 2008 | 760 | 0.140 |
Why?
|
| Keratolytic Agents | 1 | 1995 | 20 | 0.140 |
Why?
|
| Mice, Mutant Strains | 1 | 2017 | 634 | 0.140 |
Why?
|
| Immunoenzyme Techniques | 4 | 2013 | 1165 | 0.140 |
Why?
|
| Cell Differentiation | 8 | 2011 | 4078 | 0.140 |
Why?
|
| Gene Transfer Techniques | 6 | 2003 | 716 | 0.140 |
Why?
|
| COS Cells | 4 | 2005 | 377 | 0.140 |
Why?
|
| Neoplasms, Experimental | 2 | 2018 | 750 | 0.140 |
Why?
|
| Recombinant Proteins | 4 | 2017 | 2927 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2020 | 677 | 0.140 |
Why?
|
| Carbon Dioxide | 1 | 2017 | 313 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2008 | 7551 | 0.130 |
Why?
|
| Cell Line | 6 | 2017 | 5114 | 0.130 |
Why?
|
| B7-H1 Antigen | 3 | 2020 | 1022 | 0.130 |
Why?
|
| Transcription Factor AP-1 | 1 | 1996 | 246 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2004 | 1493 | 0.130 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2015 | 101 | 0.130 |
Why?
|
| Alleles | 4 | 2008 | 2437 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 1586 | 0.130 |
Why?
|
| Sialoglycoproteins | 1 | 2015 | 151 | 0.130 |
Why?
|
| Double-Blind Method | 5 | 2010 | 2588 | 0.130 |
Why?
|
| Histones | 1 | 2002 | 1466 | 0.130 |
Why?
|
| Enzyme Induction | 1 | 2015 | 249 | 0.130 |
Why?
|
| Chemoprevention | 3 | 2007 | 241 | 0.130 |
Why?
|
| Interleukin-1 | 2 | 2009 | 461 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2014 | 4938 | 0.120 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2006 | 611 | 0.120 |
Why?
|
| Camptothecin | 3 | 2003 | 517 | 0.120 |
Why?
|
| Phenotype | 4 | 2021 | 6295 | 0.120 |
Why?
|
| Respiration | 3 | 2008 | 447 | 0.120 |
Why?
|
| Cyclooxygenase 2 | 4 | 2007 | 483 | 0.120 |
Why?
|
| 3' Untranslated Regions | 2 | 2015 | 343 | 0.120 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1997 | 445 | 0.120 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 226 | 0.110 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2013 | 78 | 0.110 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 1994 | 234 | 0.110 |
Why?
|
| Phosphoproteins | 2 | 2017 | 1152 | 0.110 |
Why?
|
| Etoposide | 7 | 2004 | 870 | 0.110 |
Why?
|
| Adult | 32 | 2021 | 77950 | 0.110 |
Why?
|
| Genomics | 2 | 2021 | 2738 | 0.110 |
Why?
|
| Anilides | 1 | 2015 | 268 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2015 | 607 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 252 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 4 | 2003 | 1290 | 0.110 |
Why?
|
| GTP-Binding Proteins | 1 | 1994 | 321 | 0.110 |
Why?
|
| Amifostine | 2 | 2004 | 97 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2016 | 1546 | 0.110 |
Why?
|
| Receptor, ErbB-2 | 3 | 2014 | 2518 | 0.110 |
Why?
|
| Immune Tolerance | 1 | 2014 | 403 | 0.110 |
Why?
|
| Radiation-Protective Agents | 2 | 2004 | 128 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2014 | 703 | 0.110 |
Why?
|
| Cellular Microenvironment | 1 | 2012 | 41 | 0.110 |
Why?
|
| Molecular Sequence Data | 5 | 2011 | 6089 | 0.100 |
Why?
|
| Matrix Metalloproteinases | 1 | 2012 | 143 | 0.100 |
Why?
|
| Hydrogels | 1 | 2012 | 123 | 0.100 |
Why?
|
| Tyrosine | 2 | 2005 | 498 | 0.100 |
Why?
|
| Doxycycline | 1 | 2012 | 178 | 0.100 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2003 | 243 | 0.100 |
Why?
|
| RNA, Small Interfering | 4 | 2015 | 2216 | 0.100 |
Why?
|
| Mouth Mucosa | 2 | 2011 | 216 | 0.100 |
Why?
|
| AC133 Antigen | 1 | 2011 | 110 | 0.100 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 177 | 0.100 |
Why?
|
| Gene Targeting | 2 | 2014 | 292 | 0.100 |
Why?
|
| Models, Biological | 6 | 2015 | 3254 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 1249 | 0.100 |
Why?
|
| Genetic Vectors | 6 | 2003 | 1694 | 0.100 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2012 | 202 | 0.100 |
Why?
|
| Telomerase | 3 | 2004 | 525 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2004 | 287 | 0.100 |
Why?
|
| Perfusion | 1 | 2012 | 293 | 0.090 |
Why?
|
| Cellular Senescence | 2 | 2017 | 382 | 0.090 |
Why?
|
| Biopsy | 5 | 2003 | 3443 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2011 | 234 | 0.090 |
Why?
|
| Biological Therapy | 2 | 2002 | 58 | 0.090 |
Why?
|
| Isotretinoin | 2 | 2007 | 158 | 0.090 |
Why?
|
| Repressor Proteins | 2 | 2004 | 1664 | 0.090 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2013 | 272 | 0.090 |
Why?
|
| Biomarkers | 5 | 2011 | 5047 | 0.090 |
Why?
|
| Peptide Fragments | 2 | 2015 | 1271 | 0.090 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1990 | 36 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 709 | 0.090 |
Why?
|
| DNA Methylation | 5 | 2016 | 2669 | 0.090 |
Why?
|
| GATA3 Transcription Factor | 1 | 2011 | 146 | 0.090 |
Why?
|
| Cell Separation | 1 | 2012 | 612 | 0.090 |
Why?
|
| Terpenes | 1 | 1990 | 34 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 984 | 0.090 |
Why?
|
| Retroviridae | 2 | 1990 | 332 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 980 | 0.090 |
Why?
|
| Bioreactors | 3 | 2015 | 49 | 0.090 |
Why?
|
| Sorbitol | 1 | 2009 | 28 | 0.090 |
Why?
|
| Adenoma | 2 | 2005 | 716 | 0.090 |
Why?
|
| Hydroxylation | 2 | 2022 | 65 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 6 | 2014 | 6942 | 0.090 |
Why?
|
| Escherichia coli Proteins | 1 | 2012 | 359 | 0.090 |
Why?
|
| Sweetening Agents | 1 | 2009 | 33 | 0.090 |
Why?
|
| Immunoblotting | 3 | 2011 | 886 | 0.090 |
Why?
|
| Celecoxib | 1 | 2010 | 200 | 0.090 |
Why?
|
| DNA Damage | 2 | 2014 | 1954 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2015 | 621 | 0.090 |
Why?
|
| Receptors, Growth Factor | 1 | 2010 | 157 | 0.090 |
Why?
|
| Prognosis | 6 | 2022 | 21713 | 0.090 |
Why?
|
| Gene Expression | 5 | 2012 | 3570 | 0.090 |
Why?
|
| Tissue Engineering | 1 | 2012 | 269 | 0.090 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2009 | 85 | 0.090 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2009 | 93 | 0.090 |
Why?
|
| RNA Interference | 2 | 2010 | 1408 | 0.090 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1992 | 328 | 0.080 |
Why?
|
| Jagged-1 Protein | 1 | 2009 | 101 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 612 | 0.080 |
Why?
|
| Inflammation | 2 | 2022 | 2522 | 0.080 |
Why?
|
| Carcinogens | 1 | 1990 | 384 | 0.080 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2008 | 23 | 0.080 |
Why?
|
| Centrosome | 2 | 2019 | 95 | 0.080 |
Why?
|
| Epiregulin | 1 | 2008 | 14 | 0.080 |
Why?
|
| Cricetinae | 1 | 2009 | 706 | 0.080 |
Why?
|
| Glycoproteins | 2 | 2011 | 747 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 1533 | 0.080 |
Why?
|
| Binding Sites | 2 | 2010 | 2171 | 0.080 |
Why?
|
| Rats | 6 | 2014 | 6086 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 769 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 1992 | 529 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 376 | 0.080 |
Why?
|
| In Situ Hybridization | 4 | 2003 | 1037 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2002 | 852 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2015 | 2063 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 1999 | 311 | 0.070 |
Why?
|
| ras Proteins | 1 | 2011 | 770 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2330 | 0.070 |
Why?
|
| Aerosols | 2 | 2008 | 158 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2011 | 1732 | 0.070 |
Why?
|
| Chemokine CXCL2 | 1 | 2006 | 35 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2009 | 1265 | 0.070 |
Why?
|
| Chemokine CXCL1 | 1 | 2006 | 60 | 0.070 |
Why?
|
| Phosphoserine | 1 | 2006 | 107 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2008 | 3203 | 0.070 |
Why?
|
| Escherichia coli | 1 | 2012 | 1203 | 0.070 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2007 | 190 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2011 | 1385 | 0.070 |
Why?
|
| Ultraviolet Rays | 2 | 2005 | 575 | 0.070 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2005 | 42 | 0.070 |
Why?
|
| Tobacco Use Disorder | 1 | 2008 | 284 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 1062 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2011 | 717 | 0.070 |
Why?
|
| Aniline Compounds | 1 | 2007 | 177 | 0.070 |
Why?
|
| Point Mutation | 2 | 2002 | 769 | 0.070 |
Why?
|
| Quinazolines | 2 | 2011 | 923 | 0.070 |
Why?
|
| Macrophages, Alveolar | 1 | 2005 | 67 | 0.060 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2005 | 116 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2006 | 549 | 0.060 |
Why?
|
| Monocytes | 1 | 2009 | 788 | 0.060 |
Why?
|
| Acid Anhydride Hydrolases | 2 | 2008 | 84 | 0.060 |
Why?
|
| Peptides | 1 | 2011 | 1479 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2008 | 837 | 0.060 |
Why?
|
| Radiation Pneumonitis | 2 | 2004 | 301 | 0.060 |
Why?
|
| Oxides | 1 | 2005 | 211 | 0.060 |
Why?
|
| Arsenicals | 1 | 2005 | 201 | 0.060 |
Why?
|
| 3T3 Cells | 1 | 2005 | 355 | 0.060 |
Why?
|
| Cell Growth Processes | 2 | 2020 | 342 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 1990 | 1294 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2020 | 1077 | 0.060 |
Why?
|
| Endothelial Cells | 2 | 2009 | 1048 | 0.060 |
Why?
|
| Carcinogenesis | 2 | 2020 | 1026 | 0.060 |
Why?
|
| Genes, Retinoblastoma | 1 | 2003 | 86 | 0.060 |
Why?
|
| Hyperplasia | 1 | 2005 | 557 | 0.060 |
Why?
|
| Quinolines | 1 | 2007 | 383 | 0.060 |
Why?
|
| Tetrahydronaphthalenes | 2 | 2011 | 116 | 0.060 |
Why?
|
| Ferrous Compounds | 1 | 2023 | 13 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2009 | 1081 | 0.060 |
Why?
|
| Time Factors | 6 | 2014 | 12926 | 0.060 |
Why?
|
| Drug Resistance | 3 | 1994 | 587 | 0.060 |
Why?
|
| Ubiquitin | 1 | 2005 | 344 | 0.060 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2022 | 73 | 0.050 |
Why?
|
| Lac Operon | 1 | 2002 | 122 | 0.050 |
Why?
|
| Radiographic Image Enhancement | 1 | 2005 | 402 | 0.050 |
Why?
|
| Pneumonia | 1 | 2008 | 751 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 528 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2002 | 231 | 0.050 |
Why?
|
| Cyclins | 1 | 2004 | 456 | 0.050 |
Why?
|
| Nitriles | 1 | 2007 | 906 | 0.050 |
Why?
|
| COUP Transcription Factor I | 1 | 2022 | 81 | 0.050 |
Why?
|
| 14-3-3 Proteins | 1 | 2022 | 143 | 0.050 |
Why?
|
| Survival Rate | 7 | 2013 | 12221 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 1538 | 0.050 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2001 | 28 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2002 | 331 | 0.050 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 94 | 0.050 |
Why?
|
| Vinblastine | 1 | 2002 | 453 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2002 | 155 | 0.050 |
Why?
|
| Lymphoma | 1 | 1990 | 1467 | 0.050 |
Why?
|
| HeLa Cells | 1 | 2005 | 1643 | 0.050 |
Why?
|
| Smegmamorpha | 1 | 2020 | 4 | 0.050 |
Why?
|
| Acetylation | 1 | 2002 | 508 | 0.050 |
Why?
|
| Pyrimidines | 2 | 2019 | 3518 | 0.050 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2020 | 24 | 0.050 |
Why?
|
| Carcinogenicity Tests | 1 | 2000 | 70 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2000 | 48 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2000 | 33 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2002 | 244 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2020 | 54 | 0.050 |
Why?
|
| Pleural Neoplasms | 2 | 2007 | 470 | 0.050 |
Why?
|
| Indicators and Reagents | 1 | 2000 | 128 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 644 | 0.050 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2020 | 35 | 0.050 |
Why?
|
| Drug Synergism | 2 | 1994 | 1313 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2000 | 43 | 0.050 |
Why?
|
| Lipolysis | 1 | 2020 | 108 | 0.050 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2020 | 59 | 0.050 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 198 | 0.050 |
Why?
|
| DNA, Neoplasm | 5 | 2002 | 1910 | 0.050 |
Why?
|
| Laminin | 1 | 2000 | 194 | 0.050 |
Why?
|
| Thionucleotides | 1 | 2000 | 65 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2000 | 80 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2002 | 351 | 0.050 |
Why?
|
| Mesothelioma | 2 | 2007 | 544 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2020 | 181 | 0.040 |
Why?
|
| Combined Modality Therapy | 7 | 2004 | 8865 | 0.040 |
Why?
|
| Luminescent Proteins | 1 | 2000 | 289 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 1217 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2008 | 9244 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2008 | 1021 | 0.040 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 1999 | 16 | 0.040 |
Why?
|
| Claudin-3 | 1 | 2019 | 7 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2020 | 369 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2008 | 10001 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 424 | 0.040 |
Why?
|
| Desmoplakins | 1 | 2019 | 22 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2003 | 749 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2020 | 717 | 0.040 |
Why?
|
| Protein Phosphatase 1 | 1 | 1999 | 79 | 0.040 |
Why?
|
| Genetic Markers | 2 | 2011 | 974 | 0.040 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 1998 | 19 | 0.040 |
Why?
|
| Exons | 1 | 2002 | 1328 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 4844 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 521 | 0.040 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 1998 | 54 | 0.040 |
Why?
|
| Transcription Factor DP1 | 1 | 1998 | 57 | 0.040 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 1998 | 35 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2005 | 2803 | 0.040 |
Why?
|
| Genes, fos | 1 | 1998 | 53 | 0.040 |
Why?
|
| E2F4 Transcription Factor | 1 | 1998 | 30 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2000 | 694 | 0.040 |
Why?
|
| Rhodamines | 1 | 1998 | 49 | 0.040 |
Why?
|
| E2F Transcription Factors | 1 | 1998 | 132 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 1998 | 329 | 0.040 |
Why?
|
| Serine | 2 | 2012 | 388 | 0.040 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2017 | 3 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2011 | 1064 | 0.040 |
Why?
|
| Receptors, Oncostatin M | 1 | 2017 | 8 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2015 | 3033 | 0.040 |
Why?
|
| Paclitaxel | 3 | 2003 | 1996 | 0.040 |
Why?
|
| DNA | 1 | 2006 | 2693 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 1999 | 602 | 0.040 |
Why?
|
| Neoplasm Staging | 5 | 2017 | 13658 | 0.040 |
Why?
|
| Anthracenes | 1 | 2017 | 48 | 0.040 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 1998 | 160 | 0.040 |
Why?
|
| Replication Protein C | 1 | 1997 | 18 | 0.040 |
Why?
|
| Animals, Newborn | 2 | 2013 | 1338 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 216 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2015 | 566 | 0.040 |
Why?
|
| Aged, 80 and over | 10 | 2004 | 29902 | 0.040 |
Why?
|
| Transforming Growth Factor alpha | 2 | 1994 | 95 | 0.040 |
Why?
|
| Neutropenia | 2 | 1999 | 968 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2000 | 726 | 0.040 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2021 | 406 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 1997 | 110 | 0.040 |
Why?
|
| Isomerism | 1 | 1996 | 63 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2002 | 1353 | 0.040 |
Why?
|
| Cell Cycle | 3 | 2013 | 2084 | 0.040 |
Why?
|
| Cyclophilins | 1 | 2016 | 32 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1997 | 290 | 0.030 |
Why?
|
| GATA5 Transcription Factor | 1 | 2015 | 4 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2020 | 1489 | 0.030 |
Why?
|
| Cycloheximide | 1 | 1995 | 97 | 0.030 |
Why?
|
| Tendons | 1 | 2016 | 84 | 0.030 |
Why?
|
| Plasmids | 1 | 1998 | 837 | 0.030 |
Why?
|
| Azacitidine | 1 | 2002 | 1149 | 0.030 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1995 | 71 | 0.030 |
Why?
|
| Dactinomycin | 1 | 1995 | 145 | 0.030 |
Why?
|
| GATA4 Transcription Factor | 1 | 2015 | 45 | 0.030 |
Why?
|
| Cadherins | 1 | 2019 | 660 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 1997 | 2307 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 5539 | 0.030 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2015 | 33 | 0.030 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2015 | 65 | 0.030 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 716 | 0.030 |
Why?
|
| Clone Cells | 2 | 1994 | 555 | 0.030 |
Why?
|
| Tumor Burden | 2 | 2013 | 1987 | 0.030 |
Why?
|
| Drug Administration Schedule | 4 | 2003 | 3472 | 0.030 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2015 | 50 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 1999 | 4744 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 6009 | 0.030 |
Why?
|
| Cell Count | 1 | 1995 | 508 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 289 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2015 | 144 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2014 | 133 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1997 | 641 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 114 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2002 | 1411 | 0.030 |
Why?
|
| Diglycerides | 1 | 1993 | 37 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 3578 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2002 | 3821 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1048 | 0.030 |
Why?
|
| Clinical Trials as Topic | 3 | 1999 | 3719 | 0.030 |
Why?
|
| Infusions, Intravenous | 3 | 2003 | 1382 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 278 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2015 | 204 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1993 | 164 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2014 | 256 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 1994 | 358 | 0.030 |
Why?
|
| Cytosol | 1 | 1993 | 238 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2016 | 745 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2000 | 3005 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2014 | 135 | 0.030 |
Why?
|
| beta Carotene | 2 | 2007 | 76 | 0.030 |
Why?
|
| Acetamides | 1 | 1994 | 113 | 0.030 |
Why?
|
| DNA Replication | 1 | 1997 | 744 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 1038 | 0.030 |
Why?
|
| Sex Factors | 2 | 2007 | 2139 | 0.030 |
Why?
|
| Discs Large Homolog 1 Protein | 1 | 2012 | 9 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 1997 | 1005 | 0.030 |
Why?
|
| Survival Analysis | 4 | 2008 | 9180 | 0.030 |
Why?
|
| Immunity | 1 | 2014 | 342 | 0.030 |
Why?
|
| Treatment Outcome | 8 | 2011 | 32848 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 1994 | 257 | 0.030 |
Why?
|
| Myosins | 1 | 2012 | 96 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2012 | 392 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2013 | 354 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1992 | 185 | 0.020 |
Why?
|
| Proteins | 1 | 1999 | 1963 | 0.020 |
Why?
|
| Research Design | 2 | 2007 | 1544 | 0.020 |
Why?
|
| Oncogene Proteins v-raf | 1 | 1990 | 1 | 0.020 |
Why?
|
| Oncogene Protein p55(v-myc) | 1 | 1990 | 19 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2019 | 10035 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2013 | 442 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 571 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2012 | 429 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1993 | 850 | 0.020 |
Why?
|
| Microscopy | 1 | 2011 | 182 | 0.020 |
Why?
|
| Receptor, ErbB-4 | 1 | 2009 | 23 | 0.020 |
Why?
|
| Bronchioles | 1 | 2009 | 7 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1990 | 406 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1990 | 202 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2011 | 388 | 0.020 |
Why?
|
| Genes, erbB | 1 | 2009 | 26 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 423 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 580 | 0.020 |
Why?
|
| Genes, APC | 1 | 2009 | 70 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 1994 | 889 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 992 | 0.020 |
Why?
|
| Topotecan | 2 | 2003 | 239 | 0.020 |
Why?
|
| Logistic Models | 1 | 1996 | 3441 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2004 | 542 | 0.020 |
Why?
|
| Chemokine CXCL5 | 1 | 2008 | 13 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2011 | 397 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 328 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2000 | 448 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 1993 | 1681 | 0.020 |
Why?
|
| Uteroglobin | 1 | 2008 | 54 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 615 | 0.020 |
Why?
|
| Autophagy | 1 | 2015 | 927 | 0.020 |
Why?
|
| Porins | 1 | 2008 | 55 | 0.020 |
Why?
|
| Miniaturization | 1 | 2008 | 47 | 0.020 |
Why?
|
| Naphthols | 1 | 2008 | 25 | 0.020 |
Why?
|
| Carcinoma | 2 | 1997 | 2578 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 3251 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 471 | 0.020 |
Why?
|
| Prospective Studies | 3 | 1998 | 12873 | 0.020 |
Why?
|
| Tobacco Use Cessation | 1 | 2008 | 28 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2008 | 125 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 1994 | 2315 | 0.020 |
Why?
|
| Body Temperature | 1 | 2008 | 158 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2008 | 254 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 4975 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 1996 | 4892 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2007 | 26 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2007 | 77 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2291 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 345 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 677 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 300 | 0.020 |
Why?
|
| Vitamin A | 1 | 2007 | 94 | 0.020 |
Why?
|
| Integrases | 1 | 2008 | 262 | 0.020 |
Why?
|
| Plasmacytoma | 1 | 1988 | 111 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2007 | 143 | 0.020 |
Why?
|
| Transgenes | 1 | 2008 | 557 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 4988 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2008 | 519 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1990 | 783 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 360 | 0.020 |
Why?
|
| Carcinogens, Environmental | 1 | 2005 | 26 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2002 | 1299 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2008 | 332 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2007 | 591 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2007 | 447 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1990 | 2314 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1994 | 1350 | 0.020 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2004 | 64 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 4549 | 0.020 |
Why?
|
| Agranulocytosis | 1 | 2004 | 79 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2005 | 192 | 0.020 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2004 | 133 | 0.020 |
Why?
|
| Homeostasis | 1 | 2009 | 950 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 437 | 0.010 |
Why?
|
| Pulmonary Ventilation | 1 | 2004 | 45 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 1399 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2004 | 224 | 0.010 |
Why?
|
| Aspirin | 1 | 2007 | 455 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2004 | 198 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 548 | 0.010 |
Why?
|
| Precision Medicine | 1 | 2011 | 1154 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2009 | 1498 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 2005 | 288 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 1443 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 334 | 0.010 |
Why?
|
| Karyotyping | 1 | 2004 | 1022 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2011 | 2054 | 0.010 |
Why?
|
| Neurons | 1 | 1993 | 2287 | 0.010 |
Why?
|
| Organic Anion Transporters, Sodium-Dependent | 1 | 2002 | 26 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2008 | 1029 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 1819 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2004 | 476 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 756 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2008 | 1145 | 0.010 |
Why?
|
| Triglycerides | 1 | 2005 | 603 | 0.010 |
Why?
|
| Antibodies, Viral | 2 | 2000 | 1320 | 0.010 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2005 | 430 | 0.010 |
Why?
|
| Cyclooxygenase 1 | 1 | 2002 | 67 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2007 | 1085 | 0.010 |
Why?
|
| DNA Modification Methylases | 1 | 2002 | 172 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2005 | 875 | 0.010 |
Why?
|
| Cholesterol | 1 | 2005 | 658 | 0.010 |
Why?
|
| Thrombocytopenia | 2 | 1998 | 846 | 0.010 |
Why?
|
| Symporters | 1 | 2002 | 98 | 0.010 |
Why?
|
| Telomere | 1 | 2004 | 505 | 0.010 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2002 | 196 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2003 | 2594 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2002 | 359 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 664 | 0.010 |
Why?
|
| Esophagitis | 1 | 2002 | 202 | 0.010 |
Why?
|
| Response Elements | 1 | 2000 | 193 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 4298 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2000 | 164 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 2000 | 181 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 2232 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 2004 | 445 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2000 | 383 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 925 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2000 | 429 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 1213 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2000 | 699 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2004 | 1555 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2000 | 419 | 0.010 |
Why?
|
| Filgrastim | 1 | 1998 | 191 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 2086 | 0.010 |
Why?
|
| Infusion Pumps | 1 | 1998 | 61 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2000 | 675 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 1998 | 166 | 0.010 |
Why?
|
| Ifosfamide | 1 | 1998 | 344 | 0.010 |
Why?
|
| DNA Probes | 1 | 1997 | 217 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 1555 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1999 | 694 | 0.010 |
Why?
|
| Pregnancy | 1 | 2009 | 7573 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 3842 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1999 | 1471 | 0.010 |
Why?
|
| Leukopenia | 1 | 1996 | 151 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 1997 | 575 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2003 | 1824 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2000 | 1688 | 0.010 |
Why?
|
| Fever | 1 | 1998 | 497 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2004 | 14889 | 0.010 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 1994 | 17 | 0.010 |
Why?
|
| Heterozygote | 1 | 1997 | 1020 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 2283 | 0.010 |
Why?
|
| EGF Family of Proteins | 1 | 1993 | 28 | 0.010 |
Why?
|
| Amphiregulin | 1 | 1993 | 32 | 0.010 |
Why?
|
| Transforming Growth Factors | 1 | 1993 | 40 | 0.010 |
Why?
|
| Autoradiography | 1 | 1992 | 132 | 0.010 |
Why?
|
| Growth Substances | 1 | 1993 | 300 | 0.010 |
Why?
|
| Liver | 1 | 2002 | 2961 | 0.010 |
Why?
|
| Patient Selection | 1 | 1999 | 2055 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 2 | 1998 | 3976 | 0.010 |
Why?
|
| United States | 1 | 2007 | 15433 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2001 | 6869 | 0.010 |
Why?
|
| RNA | 1 | 1993 | 1013 | 0.000 |
Why?
|
| Risk Factors | 1 | 2003 | 17523 | 0.000 |
Why?
|
| Recombination, Genetic | 1 | 1988 | 613 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1995 | 15694 | 0.000 |
Why?
|